https://www.selleckchem.com/products/dcemm1.html 833. Importantly, HA alone yielded an AUROC of 0.828. Detection of CSPH in strictly compensated ACLD (cACLD) patients was less accurate AUROC0.759 (P less then 0.001). CSPH was ruled-in by ELF≥11.1 with a PPV of 98% (sensitivity61%/specificity92%/NPV24%), but CSPH could not be ruled-out. ELF score had a low AUROC of 0.677 (0.60-0.75; P less then 0.001) for the diagnosis of high-risk portal hypertension (HRPH; HVPG≥20mmHg) and thus, HRPH could not be ruled-in by ELF. However, ELF less then 10.1 ruled-out HRPH with a NPV of 95% (sensitivity97%/specificity26%/PPV39%). CONCLUSION The ELF score correlates with HVPG at values less then 20 mmHg. An ELF ≥11.1 identifies patients with a high probability of CSPH, while an ELF less then 10.1 may be used to rule-out HRPH. This article is protected by copyright. All rights reserved.To better understand the molecular basis of cancer, the NCI's Clinical Proteomics Tumor Analysis Consortium (CPTAC) has been performing comprehensive large-scale proteogenomic characterizations of multiple cancer types. Gene and protein regulatory networks are subsequently being derived based on these proteogenomic profiles, which serve as tools to gain systems-level understanding of the molecular regulatory factories underlying these diseases. On the other hand, it remains a challenge to effectively visualize and navigate the resulting network models, which capture higher order structures in the proteogenomic profiles. There is a pressing need to have a new open community resource tool for intuitive visual exploration, interpretation and communication of these gene/protein regulatory networks by the cancer research community. In this work, we introduce ProNetView-ccRCC (http//ccrcc.cptac-network-view.org/), an interactive web-based network exploration portal for investigating phosphopeptide co-expression network inferred based on the CPTAC clear cell renal cell carcinoma (ccRCC) phosphoproteomics data.